PD-1/Pd-L1 inhibitors
Inventors
Aktoudianakis, Evangelos • Cho, Aesop • Du, Zhimin • Graupe, Michael • Lad, Lateshkumar Thakorlal • Machicao Tello, Paulo A. • Medley, Jonathan William • Metobo, Samuel E. • Mukherjee, Prasenjit Kumar • NADUTHAMBI, DEVAN • Parkhill, Eric Q. • Phillips, Barton W. • Simonovich, Scott Preston • Squires, Neil H. • Wang, Peiyuan • Watkins, William J. • Xu, Jie • Yang, Kin Shing • Ziebenhaus, Christopher Allen
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
Core Innovation
The invention relates to inhibiting PD-1, PD-L1 and/or the PD-1/PD-L1 interaction by administering a compound of Formula (IIId), or a pharmaceutically acceptable salt thereof, to a human. Formula (IIId) defines a broad chemical structure with variable substituents including Z1 as halo and Z3 as halo or —O—C1-6 alkyl, together with extensive definitions for R1, R2, Ra, Rb, Rf, and Rg and optional ring formation.
The disclosed structures include substituted aromatic, heteroaromatic, and heterocyclic scaffolds with chloro substituents, alkoxy substituents, and functional groups such as amide, sulfonamide, carbonyl, nitrile, hydroxyl, and amino-containing moieties. The examples and figure captions depict multiple Formula (IIId) members with variations in ring systems, linker elements, and stereochemical forms, while remaining within the PD-1/PD-L1 inhibitory scaffold.
The patent frames the subject matter around a pharmaceutical method for PD-1, PD-L1 and/or the PD-1/PD-L1 interaction inhibition in humans, and the claims also encompass co-administration with selected anticancer agents or therapies, including nivolumab, pembrolizumab, atezolizumab, and ipilimumab. The document further references biological and assay support for compound 139, including PD-1/PD-L1 signaling assays, HBV-specific T-cell effector function, and a human PD-L1-expressing MC38 mouse model.
Claims Coverage
The consolidated claim coverage centers on one independent method claim directed to inhibiting PD-1, PD-L1 and/or the PD-1/PD-L1 interaction by administering a compound of Formula (IIId) (or a pharmaceutically acceptable salt thereof) to a human. The inventive scope is defined by the Formula (IIId) substituent rules and by optional dependent refinements for co-therapy and specific compound selection.
Administration of a Formula (IIId) compound for PD-1/PD-L1 inhibition
A method for inhibiting PD-1, PD-L1 and/or the PD-1/PD-L1 interaction comprising administering a compound of Formula (IIId), or a pharmaceutically acceptable salt thereof, to a human.
Z1 and Z3 substitution constraints
In Formula (IIId), each Z1 is independently halo, and each Z3 is independently halo or —O—C1-6 alkyl.
Broad R1 and R2 substituent definitions
In Formula (IIId), each R1 and each R2 is independently selected from broad alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl, and alkylheterocyclyl groups, including carbonyl- and sulfonyl-containing variants and optional substitution patterns.
Heterocyclyl formation from R1 and R2
R1 and R2 may combine to form a heterocyclyl group optionally containing additional heteroatoms independently selected from oxygen, sulfur, and nitrogen, and optionally substituted as recited in the claim.
Ring formation from Ra and Rb
Ra and Rb may combine to form a ring of 3-8 ring atoms that are C, N, O, or S, with optional substitution by groups selected in the claim.
Co-administration with selected anticancer agents or therapies
The method further includes administering at least one selected anticancer agent or therapy from the listed options.
Selected immunotherapies
The anticancer agent or therapy is selected from nivolumab, pembrolizumab, atezolizumab, or ipilimumab.
Overall, the claims cover a human method for inhibiting PD-1, PD-L1 and/or the PD-1/PD-L1 interaction by administering a Formula (IIId) compound or pharmaceutically acceptable salt, with inventive scope driven by the Z1/Z3 constraints, broad R-group definitions, optional heterocyclyl and ring formation, and dependent co-therapy refinements.
Stated Advantages
Inhibiting PD-1, PD-L1 and/or the PD-1/PD-L1 interaction in a human.
High tumor PD-L1 target occupancy (greater than 90% for at least 24 h).
Tumor growth inhibition comparable to an anti–PD-L1 antibody.
Tolerability described as no body-weight effect.
Enhanced HBV-specific CD8+ and CD4+ T-cell antiviral effector functions with increased IFN-γ and granzyme B compared to durvalumab.
Documented Applications
A method for inhibiting PD-1, PD-L1 and/or the PD-1/PD-L1 interaction by administering a Formula (IIId) compound to a human.
Co-administration with selected anticancer agents or therapies, including nivolumab, pembrolizumab, atezolizumab, or ipilimumab.
Treating cancer, including many tumor types listed in the provided content, by inhibiting PD-1, PD-L1 and/or the PD-1/PD-L1 interaction.
Treating PD-1/PD-L1-mediated conditions described in the provided content.
Enhancing HBV-specific CD8+ and CD4+ T-cell antiviral effector functions in chronic hepatitis B context.
Use in a human PD-L1-expressing MC38 mouse model showing PD-L1 target occupancy and tumor growth inhibition.
Interested in licensing this patent?